Replimune Group Inc
NASDAQ:REPL

Watchlist Manager
Replimune Group Inc Logo
Replimune Group Inc
NASDAQ:REPL
Watchlist
Price: 9.78 USD -3.46% Market Closed
Market Cap: 753.2m USD

Relative Value

There is not enough data to reliably calculate the relative value of REPL.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

REPL Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.1
Forward
29.4
vs History
vs Industry
Median 3Y
-4.5
Median 5Y
-6.8
Industry
23
Forward
-3.3
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-9.3
Industry
19.4
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-9.7
Industry
23.1
vs History
69
vs Industry
45
Median 3Y
1.9
Median 5Y
2.2
Industry
2.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.5
Forward
13.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.4
vs History
vs Industry
27
Median 3Y
-2.6
Median 5Y
-4.1
Industry
4.4
Forward
-1.4
vs History
vs Industry
26
Median 3Y
-2.5
Median 5Y
-4.1
Industry
4.5
Forward
-1.3
vs History
vs Industry
30
Median 3Y
-3.3
Median 5Y
-5.5
Industry
5.2
vs History
vs Industry
25
Median 3Y
-3.2
Median 5Y
-5.3
Industry
3.7
vs History
73
vs Industry
26
Median 3Y
7.8
Median 5Y
9.3
Industry
4.8

Multiples Across Competitors

REPL Competitors Multiples
Replimune Group Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Replimune Group Inc
NASDAQ:REPL
753.9m USD 0 -3 -1.3 -1.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 476 503.8 -163 861.7 -198 980.4 -196 709.8
US
Abbvie Inc
NYSE:ABBV
338.2B USD 5.9 81.4 15.5 22.9
US
Amgen Inc
NASDAQ:AMGN
157.2B USD 4.6 26.5 14.3 23.5
US
Gilead Sciences Inc
NASDAQ:GILD
136.7B USD 4.8 22.9 10 13.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.5B USD 10.5 -117.8 25 26.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 043.4 -521.4 -567.8 -552.6
AU
CSL Ltd
ASX:CSL
116.6B AUD 5 27.6 17.1 21.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
56.1B USD 4 12.5 11.1 12.4
US
Seagen Inc
F:SGT
39.3B EUR 19.7 -60.4 -65 -58.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
39.1B USD 16.6 -144.9 -648 -324.7
P/S Multiple
Revenue Growth P/S to Growth
US
Replimune Group Inc
NASDAQ:REPL
Average P/S: 3 447 861.8
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 476 503.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.5
10%
1
US
E
Epizyme Inc
F:EPE
2 043.4
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4
4%
1
US
S
Seagen Inc
F:SGT
19.7
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.6
29%
0.6
P/E Multiple
Earnings Growth PEG
US
Replimune Group Inc
NASDAQ:REPL
Average P/E: 34.2
Negative Multiple: -3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -163 861.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.4
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.5
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.9
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -117.8 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.4 N/A N/A
AU
CSL Ltd
ASX:CSL
27.6
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.4 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -144.9 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Replimune Group Inc
NASDAQ:REPL
Average EV/EBITDA: 15.5
Negative Multiple: -1.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 980.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.3
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -567.8 N/A N/A
AU
CSL Ltd
ASX:CSL
17.1
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.1
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -648 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Replimune Group Inc
NASDAQ:REPL
Average EV/EBIT: 20
Negative Multiple: -1.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 709.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.5
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.2
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -552.6 N/A N/A
AU
CSL Ltd
ASX:CSL
21.3
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.4
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -324.7 N/A N/A